1. Introduction {#sec0005}
===============

Adolescence and early adulthood are defined by physiological changes, social transitions, and increased independence ([@bib0255]; [@bib0265]; [@bib0840]; [@bib0955]). Findings from animal models and human imaging have provided insight about the neurobiological changes during the transitions into and out of adolescence ([@bib0175]; [@bib0225]). Considerable work from our groups and colleagues, as well as many others, have demonstrated that adolescence is marked by increased affective lability relative to childhood and adulthood. Animal and human work has shown greater sensitivity to emotional cues during adolescence and accompanying dynamic changes in a neural circuit involving the prefrontal cortex (PFC) and connections with the amygdala and hippocampus ([@bib0110]; [@bib0170]; [@bib0300]; [@bib0825]; [@bib0905]).

Advances in medicine, along with breakthroughs in scientific research, have enabled remarkable increases in overall survival for patients with a wide range of childhood and adolescent cancers. The average survival rate for pediatric cancer has gone from 50% in the 1970s to upwards of 80--85% in the past five years ([@bib0190]; [@bib0295]). It is estimated that there will be over 500,000 survivors of childhood and adolescent cancers living in the United States alone by 2020 ([@bib0030]). While cure is - and should unequivocally be - the number one priority of pediatric oncology, genetic, molecular, and developmental cognitive neuroscience research can provide critical frameworks for understanding the variability in psychological outcomes and how to improve the quality of life in survivors.

The purpose of this review is to discuss normative neural circuitry changes during development that likely interact with the onset, treatment, and psychological outcomes of pediatric cancer. Absent from many neuro-oncology studies are the ways in which developmental changes in emotional learning and cognitive control circuitry may contribute to psychological outcomes, and to the secondary effects that are associated with cancer survivorship. Further, we consider how genetic polymorphisms that directly impact the developing brain may further influence cancer outcomes. A recent review by Marusak and colleagues ([@bib0545]) highlights the importance of considering neurodevelopment in pediatric cancer survivors while underscoring that childhood cancer can be considered a form of early life adversity. Here we extend upon the research highlighted by Marusak et al. and suggest that recognizing the ongoing neural maturation during adolescence and young adulthood is critical for understanding, and optimizing, psychological outcomes. We largely focus on the affective circuitry changes that occur during adolescence and early adulthood. There is a large body of work suggesting that frontoamygdala circuitry, which supports aversive learning, undergoes significant structural and functional changes during adolescence and young adulthood. By focusing on the neurobiology of aversive learning, we aim to understand variation in pediatric cancer outcomes, including secondary symptoms of anxiety and post-traumatic stress (PTS). We suggest that adolescence and early adulthood may provide a sensitive period for intervention to improve psychological outcomes in pediatric cancer survivors as they mature into adulthood. Building upon a literature of clinical and neuroscientific research in pediatric cancer survivors ([@bib0545]), we propose future translational research directions that bridge molecular neuroscience in animal models and human cognitive neuroimaging. The goal is to improve how we study, understand, and treat the potentially deleterious effects of pediatric cancer treatment on the developing brain to optimize capacity for learning, emotion regulation, and quality of life.

2. Background {#sec0010}
=============

Recent age-specific incidence rates from 153 cancer registries world-wide ([@bib0875]) show that for children ages 0--14 years, leukemias and tumors of the central nervous system (CNS) are most common. Following in prevalence are sympathetic nervous system tumors, retinoblastoma, renal tumors, and less frequent are hepatic, bone, soft tissue sarcomas, germ cell or epithelial tumors. Lymphomas and epithelial tumors were most prevalent in teens aged 15--19, followed by leukemias, CNS tumors, germ cell tumors, bone tumors, soft tissue sarcomas. Least frequent in this age group are renal and hepatic tumors or retinoblastoma. Unspecified or unclassified tumors make up a small percentage of tumors across all ages. High rates of leukemia, CNS tumors, and lymphomas across ages 0--19 are a consistent trend across most world regions, yet incidence rates vary between regions ([@bib0875]). Of importance to this review is that various forms of cancer emerge consistently throughout infancy, childhood and into adolescence and early adulthood (see [Fig. 1](#fig0005){ref-type="fig"}).Fig. 1**Diagnoses and treatment for pediatric and adolescent cancer coincides with periods of massive neurodevelopmental change**. Blue bars represent the incidence of pediatric cancer across development ([@bib0875]). During normal development, myelination in the brain peaks during early childhood, while synapses, neuromodulators and neurotrophins, as well as anxiety disorders, peak during early adolescence ([@bib0515]). How treatment regimens may shift these normal developmental patterns of myelination, neural connectivity, or emerging psychopathology is of interest to the developmental neuroscience community.Fig. 1

Unlike normal differentiated cells within the body, cancer cells are rapidly proliferating, undifferentiated cells that exhibit aberrant cellular signaling, immune evasion, and altered metabolism ([@bib0930]). Modern therapies designed to target cancer cells have included surgical resection for solid tumors, chemotherapeutic agents, ionizing radiation, and more recently immunotherapy, in order to alter the various features influencing a cancer cell's replicative capacity. These treatments work via a variety of mechanisms by altering microtubule stability, DNA damage response, apoptotic machinery, and generalized proliferative capacity or cellular signaling pathways. While successful in targeting rapidly dividing cancer cells, such therapeutics do not fully spare healthy proliferating cells, which can lead to off-target and unwanted side effects.

One of the most significant psychological side effects for cancer treatment is "chemo brain," a term popularized in the last decade to refer to alterations in cognitive functioning as a result of systemic chemotherapy ([@bib0830]). It is increasingly recognized that changes in cognitive functioning involving working and episodic memory, processing speed, executive functioning, and attention ([@bib0430]; [@bib0830]) may not be solely the direct result of cancer treatment but also a result of the distress surrounding treatment ([@bib0025]; [@bib0770]). In adult cancer survivors, these cognitive deficits often persist after treatment ([@bib0005]),and up to 60% experience symptoms that progressively worsen over time ([@bib0425]; [@bib0630]; [@bib0640]). Of note, at least one-third of all pediatric cancer survivors experience significant cognitive dysfunction ([@bib0235]), which we describe in greater detail in subsequent sections. Relatedly, children and adolescents often have difficulties with academic performance and peer relationships ([@bib0065]; [@bib0085]; [@bib0935]; [@bib0965]; [@bib0995]). The term 'pediatric' encompasses 18+ years of development, and combines infants, toddlers, children, adolescents, and late-adolescents into the same bracket for post-treatment analyses. Thus, while cognitive and emotional challenges following cancer treatment are well documented, how the developmental timing of cancer onset and treatment is associated with specific cognitive, emotional, and social outcomes is not as well delineated.

A significant body of research on child and adolescent cancer survivors has suggested that they experience higher rates of anxiety, PTS symptoms and emotional distress ([@bib0715]; [@bib0795]; [@bib1000]), compared to both their siblings and to healthy peers. However, prevalence estimates vary widely across studies ([@bib0090]; [@bib0865]). Recent work ([@bib0685], [@bib0690]) has aimed to address whether some estimates may be inflated by a variety of factors, including: 1) attentional bias effects created by priming respondents to reflect on their experiences with cancer/treatment as traumatic; 2) attributing all distress measured to the cancer experience without modeling additional factors that may contribute more generally; or 3) lack of an appropriate comparison group that has experienced another type of traumatic event, such as in a study that found lower rates of PTS symptoms in children who had survived cancer compared to those who were bereaved by loss of a parent ([@bib0885]). When taking these factors into account, overall rates of PTS among this population may be lower than previously estimated. However, disparate findings across studies highlight the importance of understanding with greater nuance the developmental and individual differences that *moderate* the association between childhood cancer and psychological outcomes.

Despite findings that some pediatric survivors may be at increased risk for PTS and anxiety, these remain understudied psychosocial impacts of pediatric cancer survivorship ([@bib0545]; [@bib0560]). Early life stress has been shown to increase the risk for later developing affective pathology, and a single stressor experienced during childhood increases the lifetime risk of anxiety or depressive disorders by approximately 30% ([@bib0020]). How pediatric cancer and its treatment may act as an early adverse experience for some survivors, with influences on cognitive, behavioral, and emotional outcomes, has been summarized in detail in a comprehensive review ([@bib0545]). A recent literature review of over 24 studies exploring anxiety at both the clinical and subclinical level in adolescent cancer survivors concluded that aside from PTS symptoms and clinical levels of PTSD, there was little research on anxiety more broadly ([@bib0560]). It should be noted that the risk for affective pathology in the general population increases in late childhood and peaks during adolescence and early adulthood ([@bib0100]). Therefore, it is important to carefully examine the unique risk conferred by cancer diagnosis and treatment over and above the average levels expected across development. While these disorders are treatable in many individuals, they carry with them high rates of comorbidity and recurrence that have lasting effects on educational, social, and emotional outcomes ([@bib0100]).

3. Adolescent and young adult structural and functional brain development {#sec0015}
=========================================================================

In order to begin to disentangle the physiological and psychological impacts of cancers and their treatments on the developing brain, it is important to first appreciate the significant normative changes that occur across development in both structural and functional neural connections. Animal work ([@bib0395]; [@bib0750]; [@bib0980]), human postmortem studies ([@bib0415], [@bib0420]), and neuroimaging studies ([@bib0205]; [@bib0315]; [@bib0435]) have demonstrated dynamic changes in subcortical-cortical circuitry and connections throughout the adolescent and early adult years. In the sections below, we describe in greater detail the changes in these circuits gleaned from animal models. Broadly, maturation of subcortical regions and subcortical-subcortical connections (i.e., amygdala, ventral striatum and hippocampus) occur during childhood. Maturation of the prefrontal cortex and refinement of its connections with subcortical areas (ventral medial prefrontal cortex to both the amygdala and the ventral striatum) is protracted across development and extends into early adulthood ([@bib0040]; [@bib0310]; [@bib0375]; [@bib0510]; [@bib0675]). Collectively, this large body of work has provided robust evidence that the circuits supporting cognitive control, affective processing and psychosocial behavior are dynamically changing until early adulthood ([@bib0115]; [@bib0245]; [@bib0870]).

Changes in the developing brain can be viewed in a hierarchical manner ([@bib0120]). The circuitry that supports successfully navigating the social and emotional environment is continually evolving and relies on sequential input throughout childhood and adolescence. It is thought that temporally defined cascading events can stimulate neurodevelopment and that each developmental phase is predicated on the prior phase. In the context of child and adolescent cancer, this means that significant events, such as cancer onset and treatment, can potentially disrupt the gradual emergence of functional neural connections, shift the developmental cascade, and have far-reaching downstream effects on subsequent developmental stages. Thus, the timing of cancer diagnosis and duration of treatment for the developing brain are important factors to consider when discussing neurocognitive changes associated with survivorship.

A number of studies have examined the impact of age at cancer diagnosis and time since treatment on neurocognitive and psychological outcomes, with some indication that younger patients suffer greater cognitive impacts ([@bib0730]), while adolescents and young adults may be at increased risk for psychological sequelae such as anxiety and PTS for reasons that are discussed in further detail below ([@bib0385]; [@bib0745]; [@bib0780]; [@bib0895]; [@bib0970]). However, due to the cross-sectional designs of many studies, age at diagnosis and time since treatment are often confounded, making it difficult to interpret age-related differences ([@bib0195]; [@bib0710]). Research examining cognitive versus psychological outcomes in siloes may also underestimate the full extent of disease and treatment impacts on survivors, as cognitive dysfunction itself is linked to poorer social, emotional and academic functioning ([@bib0865]; [@bib0950]). Taken together, these studies suggest that there isn't simply a linear, additive effect between age of cancer diagnosis, timing of treatment and outcomes, which highlights the need to consider the developing brain in order to better understand both the initial insult and subsequent outcomes.

4. Aversive learning -- developmental influences to consider for adolescent cancer {#sec0020}
==================================================================================

Translational research offers important evidence about the development of fear-related disorders such as anxiety and PTS across development. Investigative studies exploring aversive learning (the acquisition of fear through classical conditioning) and the malleability of fear memories at different developmental stages are relevant to pediatric cancer survivorship for several reasons. First, aversive learning and fear extinction learning provide a simplified model for probing and understanding the neural circuitry associated with subsequent anxiety and PTS often observed in cancer survivors. Second, while fear extinction learning offers insight into treating anxiety and PTS, it also provides a robust and highly reproducible model for studying perturbations in general learning behaviors, through readily available assays for assessing memory acquisition, recall, extinction, and expression. Recent work highlights 'fear of cancer recurrence' in adolescent cancer survivors as one of many social and physical variables influencing learning achievement and overall quality of life ([@bib0575]). This model system provides a framework for exploring chemotherapy or radiation-induced shifts in typical learning trajectories and can offer insight into both psychopathology and learning in general. Lastly, there has been a robust increase in aversive and fear learning studies focused on the developing brain, providing normative comparison data for these processes across developmental stages ([@bib0360]).

Through associative learning techniques based on classical conditioning principles, long-lasting, aversive memories can be quickly formed in the rodent. Animal models of fear learning are frequently relied on and regarded highly for investigating learning properties, due to their ease and experimental control, along with well-defined behavioral assays. Thus, rodent studies of aversive memory allow for the study of precise, isolated fear-learning incidents and interventions without genetic or environmental confounds influencing results. Sensitive and critical periods of aversive learning have been the focus of infant and juvenile animal models ([@bib0480], [@bib0485]; [@bib0595]; [@bib0755]; [@bib0760]). Throughout the past decade, rodent models have begun incorporating more intermediate, adolescent ages ([@bib0160]; [@bib0365]; [@bib0380]; [@bib0485]; [@bib0555]; [@bib0660], [@bib0665]; [@bib0670]; [@bib0765]; [@bib0810]), further highlighting unique sensitive periods for fear responsiveness. Recent studies have demonstrated that contextual fear is temporarily suppressed during adolescence ([@bib0660]). However, cued fear expression is enhanced, highly intact, and extinction-resistant in adolescent rodents, with parallel findings in humans ([@bib0230]; [@bib0450]; [@bib0555]; [@bib0665]). The dissociation between these two distinct forms of aversive learning has wide-ranging implications not only for understanding the adolescent brain, but also for uncovering glimpses into the unique etiology of adolescent anxiety. There are dynamic alterations between prefrontal areas and amygdala in both humans ([@bib0275],[@bib0280], [@bib0275],[@bib0280]; [@bib0305]; [@bib0645]) and rodents ([@bib0185]; [@bib0285]; [@bib0485]; [@bib0665]) that underlie successful fear extinction. During the transition through adolescence, these amygdala-prefrontal connections can become susceptible to structural or functional modifications resulting from various psychological and physiological insults to the brain, such as those associated with both the stressors and treatments of cancer. There is also recent evidence for sex differences in fear extinction in rats ([@bib0160]), which may further interact with these other factors.

The enhanced capacity for cued fear expression and diminished cued extinction in adolescent rodents coincides with a sensitve period defined by a surge in connectivity between ventral CA1 and the prelimbic cortex (PL) of the ventral medial prefrontal cortex (vmPFC) ([@bib0670]), as well as enhanced connections between PL and amygdala. These enhanced connections suggest that a temporally-dependent surge in neural wiring during adolescence may be responsible for the unique behavioral properties associated with fear in rodents and adolescent anxiety. Optogenetic exploration also shows increases in feedforward inhibition with greater spontaneous inhibitory currents in excitatory neurons during adolescence, further highlighting the structural and functional changes associated with adolescent development in a prefrontal-amygdala circuit ([@bib0035]). As these experiments demonstrate developmentally regulated shifts in neural connectivity that are both measurable and quanitifable in rodents, they provide an experimental baseline for exploring the effects of cancer treatment regimens on the developing brain. Questions such as "how does this treatment alter typically developing neural circuits?" or "how does behavior change as a result of treatment regimens and are there also changes in the underlying neural architecture?" can be examined.

It is well known from adult literature that the hippocampus is capable of modifying extinction learning via interactions with the amygdala and prefrontal cortex (PFC) ([@bib0520]; [@bib0590]; [@bib0625]; [@bib0725]; [@bib0860]). Therefore, studies were designed to maximally target the adolescent surge in vCA1-PL connectivity by combining cued and contextual extinction into one session in order to take advantage of the brain's unique heightened capacity for hippocampal-dependent extinction learning at this age ([@bib0670]). These experiments showed that extinction of adolescent-acquired fear memories could be enhanced when mice were exposed to a combined cue and contextual extinction session, which utilized the adolescent-specific surge in neural circuitry. These hippocampal-prefrontal connections are rapidly changing across adolescence and it is of interest to see how neurogenic waves and synaptic pruning associated with this stage of development may be altered by exposure to chemotherapy in children and adolescents. By utilizing what is already known about the temporally restricted increases in neural connectivity within this circuit and the simultaneous changes in aversive learning behaviors at this age, the hippocampal-prefrontal circuit provides a simplified model to further explore the effects of cancer treatment in a controlled, causal, and quantifiable way. By asking targeted questions such as "does X treatment inhibit, prolong, delay, enhance, stunt, hasten, or have no effect on this connectivity surge?" the field may be able to probe how cancer regimens impact the developing brain, first in an isolated incident-dependent way, and ultimately more broadly.

The hippocampus is involved in both cued and contextual fear processing and its developmental changes throughout adolescence are well documented across species ([@bib0060]; [@bib0500]). Shifts in neuronal or glial proliferation and apoptosis, synaptogenesis, synaptic pruning, dendritic spine remodeling, or myelination are likely contributors to the heterogeneous hippocampal development observed across childhood and adolescence. The changes correspond with volumetric increases in posterior regions and subsequent decreases in anterior regions ([@bib0330]). With connections to the PFC, amygdala, and hypothalamic pituitary axis, the anterior region of the hippocampus is a likely contributor to contextual fear alterations observed in adolescence. The changes within this region highlight an ever-changing dynamic circuit in which rodents do not exhibit contextual fear at adolescent ages, but express contextual fear to previously acquired memory later in life as adults ([@bib0045]; [@bib0125]; [@bib0660]; [@bib0680]; [@bib0700]).

How treatment-induced changes in neurogenesis may alter hippocampal development (specifically the anterior regions) and subsequent reciprocal connections in this circuitry will likely depend on patient age and genetics, as well as the particular treatment type and duration of treatment. Because neurogenesis in the subgranular zone of the dentate gyrus (DG) and subventricular zone (SVZ) of the lateral ventricle are key for learning and memory, rodent studies have sought to explore the role of cytotoxic agents on neurogenesis and decreases in neural proliferation and cell survival. Rodents demonstrated decreased neuronal proliferation and cell survival from cytotoxic agents as early as one day after treatment, and these anti-proliferative effects have been shown to last up to 6 months after treatment ([@bib0790]). Even at subclinical dosages that have no effect on tumor cells *in vitro*, certain chemotherapeutic agents can cause cell death in normal CNS progenitors and oligodendrocytes, and lead to continued increases in cell death within the SVZ, DG, and corpus callosum of mice ([@bib0210]).

Systematic review of the chemotherapy-induced cognitive impairments in rodents shows decreases in hippocampal proliferation, neurogenesis, and cell survival. These changes in cell cycle behaviors likely result from the various chemotherapy agents, including antimetabolites, DNA cross-linking agents, alkylating agents, mitotic inhibitors, microtubule destabilizers, and anti-hormonal agents. The majority of these rodent studies also reveal subsequent impairments on spatial and emotional memory tasks, yet the most of these studies were performed using adult animals ([@bib0215]). The impact of oxidative stress, myelin toxicity, neurovascular damage, inflammation, and direct cellular toxicity are identified as likely contributors to chemotherapeutic impairments on hippocampal neurogenesis and subsequent learning tasks ([@bib0215]). It is unknown how these mechanisms may differ in their insults on the developing brain, particularly on the adolescent and young adult brain, which has an increased capacity for plasticity, yet may also be more susceptible to toxicity.

Out of 22 rodent studies ([@bib0790]) investigating the effects of chemotherapy on cognition, only one examined adolescent mice ([@bib0585]), one examined late-adolescent/young adult mice ([@bib0270]), and two employed juvenile (17-day-old) rats, yet did behavioral testing in adulthood ([@bib0880]; [@bib0985]). Interestingly, the two rodent studies using common chemotherapy agents in mid- and late-adolescent ages showed opposite results on the hippocampal-dependent task of novel object recognition (NOR). The five-week-old thioTEPA-treated (C57BL/6 J) mice showed impaired NOR and the 7-8-week-old methotrexate and 5-fluorouracil-treated (C57BL/6Hsd) mice showed no impairment in NOR. While these two adolescent rodent studies comprise less than 10% of the studies reviewed, the opposing results on the same task highlight the importance of the extremely sensitive time period surrounding adolescent prefrontal-cortex-amygdala-hippocampal circuit development. These disparate results are not surprising as the former agent (thioTEPA) is an alkylating antineoplastic agent and the latter agents (methotrexate and 5-FU) are antimetabolite neoplastic agents. Their opposing influences on an identical task (NOR) confirm the need for additional studies investigating how particular agents affect certain neural circuits and behaviors. With limited research to draw upon, making broad conclusions about the neurocognitive effects of chemotherapy across development will prove difficult until the literature embodies a wider array of studies investigating different drugs, ages, and behavioral tasks. Additionally, differences in aversive learning were observed in both cue- and context-dependent tasks in the rodent studies examined, but they did not always trend in the same way, suggesting drug, dose, and age-dependent differences interact in complicated ways ([@bib0790]). Furthermore, cytostatic differences and minor genetic variation in mouse strains (C57BL/6J vs C57BL/6Hsd genetic background) in these groups add additional complexity -- would thioTEPA-treated 8-week mice show NOR impairments, similar to their younger counterparts? Only by teasing apart the precise timing of distinct molecular and genetic events can we draw meaningful conclusions about the impact of chemotherapy on neurocognitive outcomes.

In the recent review by Marusak and colleagues, the authors aptly state that "concurrent evaluation of drug exposure and threat/stress may help to more fully explain neurodevelopmental changes, and ultimately, cognitive, behavioral, and emotional consequences" ([@bib0545]). While the authors clearly outline the undeniable difficulties associated with measuring and defining adversity and a child's level of distress, there are also many molecular challenges facing the field, and readers should be cautious not to infer that serum drug exposure is an adequate measure for quantitatively assessing brain exposure, especially in a temporally-dependent context. To do so would be to ignore the importance of the blood-brain-barrier (BBB) when estimating drug concentration *within* the brain. Furthermore, relying solely on serum drug concentration does not take into consideration how the BBB may break down or become leaky as a result of various diseases, a phenomenon commonly observed in brain cancer. Utilization of rodent models in combination with the review of patient charts, self-report psychological surveys, fMRI studies, etc., may offer great insight into the developmental effects of cancer treatment. The whole may be greater than the sum of its parts when the field is able to combine fine-tuned molecular, pharmacologic, behavioral, and genetic developmental rodent studies with those of patients, survivors, and age-matched healthy human subjects.

4.1. Environmental influences on aversive learning {#sec0025}
--------------------------------------------------

Of particular importance for childhood and adolescent cancer survivors is their home, family environment, and support system ([@bib0975]). A recent review compiled studies of psychological outcomes for parents of childhood cancer survivors ([@bib0530]). While mean levels of distress, coping, and family functioning were within typical ranges, there were clinical-level elevations among some subgroups in psychological distress, and as many as 44% of parents reported severe levels of PTS symptoms. It is not difficult to imagine the downstream effects of parental distress on the parent-child relationship and family functioning. A second environment that impacts child and adolescent cancer patients is the oncology setting itself, i.e., drugs, scans, needles, surgeries, and hospital stays. The ability to distinguish cues of threat versus safety may be compromised in the pediatric oncology setting, when the very treatments designed to save the patient actually appear as threatening, painful, or scary. One avenue for future research is to conceptualize the home and treatment environments in the context of safety and threat signals ([@bib0155]; [@bib0495]). An important factor for whether an anxious child may grow up to have an adult life free from psychopathology may be whether they can reliably discriminate between the boundaries of safety and threat signals, which are distorted in individuals with anxiety disorders ([@bib0465]).

While it is well known that early life stress can shift sensitive periods of neurodevelopment, and aversive or emotional learning in particular ([@bib0055]; [@bib0105]; [@bib0220]; [@bib0460]; [@bib0655]; [@bib0820]; [@bib0910]), it is not known how the psychological and physiological insults of cancer treatment may act as stressors to similarly shift these sensitive periods in children and teens. As adolescence is already a time associated with the emergence of psychopathologies and an increase in anxiety disorders, it should be of interest to understand how prior or active cancer treatment may create additional burden on an already challenging academic or social context ([@bib0325]), and whether this may impact persistence of any such disorders into adulthood ([@bib0695]). While early studies investigating psychological functioning in adolescent survivors of cancer have yielded mixed results ([@bib0345]), others have found that despite increased PTS symptoms, survivors also exhibit increased posttraumatic growth that is dependent on age of diagnosis ([@bib0050]). According to Barakat et al., posttraumatic growth is defined as "the cognitive process by which those who have experienced trauma apply positive interpretations to and find meaning in the traumatic event," which can result in "restoration of pre-trauma schema and positive changes in one's sense of self, relationships, and philosophy of life," contributing to positive emotional outcomes ([@bib0050]). The data on posttraumatic growth supports one potentially positive outcome associated with pediatric cancer survivorship, in which there is a newfound resiliency as a result of overcoming a traumatic experience. A recent review investigating posttraumatic growth in adolescent survivors of cancer found that younger age at diagnosis as well as lower use of avoidant coping strategies predicted lower levels of psychosocial stress, suggesting avoidant coping strategies correlated with higher posttraumatic growth ([@bib0915]).

5. Learning, memory, & cognitive control in adolescent cancer survivors {#sec0030}
=======================================================================

Human neuroimaging studies that include task-based, resting state and structural studies of pediatric cancer survivors are critical for translating work from animal models. Given concerns for anxiety and PTS in pediatric cancer survivors, it makes sense to examine underlying changes in amygdala-prefrontal-cortex activity associated with emotional processing and regulation. However, task-based human imaging studies in children and adolescents who have survived cancer have largely not focused on tapping into these processes ([@bib0545]). Rather, the task-based studies have focused on primarily studying executive functioning, learning, and memory. The emphasis on these abilities is related to the significant side effects associated with cancer survivorship, such as challenges with working memory and declines in overall cognitive functioning. Future task-based neuroimaging research that explores emotional processing ([@bib0550]) as well as the intersection between emotion and cognitive control as it relates to developmental timing ([@bib0010]) will provide novel and important contributions.

Cognitive control refers to a collection of abilities including working memory, flexibility, and inhibition, which allow us to adapt and control behavior in a top-down manner in order to achieve distinct goals. Research has demonstrated that cognitive control generally follows a protracted developmental time course into young adulthood ([@bib0110]; [@bib0410]; [@bib0535]; [@bib0720]; [@bib0960]). The ability to exert developmentally appropriate cognitive control is critical for successfully navigating social relationships ([@bib0390]), academic performance ([@bib0015]; [@bib0075]), and psychological well-being. Aspects of cognitive control can be measured in a variety of ways, with tasks that target specific skills such as working memory (N-back tasks), cognitive flexibility (task-switching paradigms), and inhibition (go/no-go or stop-signal tasks). The pediatric cancer survivorship literature is mixed in terms of how cognitive control is measured and reported. Recent evidence in a sample of 130 acute lymphoblastic leukemia survivors demonstrated consistency between cognitive neuroscience behavior tasks, standardized cognitive testing, and caregiver report of executive functioning ([@bib0920]). These findings support the fluidity in which the cancer literature uses these various paradigms to study cognitive deficits. However, the explicit developmental timing of the cancer onset and treatment (e.g. during adolescence) on these cognitive functions has not been explicitly tested.

The development of cognitive control is closely coupled with the development of the PFC. A review by Crone and Steinbeis suggests that different aspects of cognitive control rely on subregions of the PFC ([@bib0180]). Specifically, stimulus-driven, deliberative cognitive control is dependent on the lateral PFC, whereas rule-based, internalized cognitive control, including emotion regulation, relies more on the medial PFC. Dividing cognitive control into sub-categories provides a context for the developmental changes that occur throughout childhood and adolescence in these abilities.

Cognitive problems, or declines in intellectual functioning including impairments in working memory and inhibition, are common for children who receive CNS-directed cancer therapies ([@bib0605]). Survivors of pediatric malignant brain tumors or acute lymphoblastic leukemia are at the greatest risk for cognitive difficulties ([@bib0600]; [@bib0635]). Human neuroimaging studies have demonstrated structural, volumetric changes in survivors ([@bib0200]; [@bib0545]; [@bib0805]). As elegantly reviewed in [@bib0545], these are associated with challenges in response inhibition on a stop signal task ([@bib0925]), as well as with challenges in executive functioning as measured by self-report on the Behavior Rating Inventory of Executive Function (BRIEF) questionnaire ([@bib0900]). The underlying cellular and molecular mechanisms that drive these structural changes are not fully understood, although a likely candidate is toxicity of treatment and disturbance to normal cell function and neural connectivity. Recent work demonstrated that non-irradiated adult survivors of childhood leukemia had alterations in functional connectivity in the brain, as well as difficulties on a set-shifting task compared to controls, but no changes in white or gray matter volume ([@bib0070]). These findings illustrate the complexities of cancer treatment and their downstream effects; they highlight how various treatments may have cumulative negative effects on brain volume and cognitive functioning. These cumulative effects may not simply be linear ([@bib0070]), with earlier treatments corresponding to worse outcomes. Because chemotherapy dosage can vary at different points during development ([@bib0070]), younger children may receive lower dosing, which can also significantly impact brain development trajectories differently.

fMRI task studies in pediatric cancer survivors have largely focused on working memory tasks (specifically, an N-back task that measures memory for sequences of stimuli). Increased activation patterns in the dorsal lateral prefrontal cortex, dorsal anterior cingulate ([@bib0735]), and areas of the medial frontal gyrus ([@bib0740]) have been found in pediatric cancer survivors, along with poorer accuracy on the task and parental ratings of executive functioning. These findings were similar to those reported by King et al., who also found that increased activation in superior and middle frontal gyrus in survivors of pediatric brain tumors during the N-back task was associated with poorer performance on the task ([@bib0490]). These results highlight neural hyperactivity, which may reflect compensatory mechanisms used for task completion. Of note, Robinson et al., tested children (average age 10 years) ([@bib0740]) and teenagers (average age 14 years) ([@bib0735]) whereas King et al. tested primarily adult survivors (17--35 years of age). Despite the similarities in results across studies, the age differences of the subjects were significant. Future studies that are powered to be able to tease apart how chemotherapy can impact developmentally typical, age-dependent changes in cognitive functioning will be informative for better understanding observed compensatory neural patterns.

Further evidence of compensatory activity patterns that support cognitive flexibility in pediatric cancer survivors comes from resting state studies showing increased strength in the default mode network, the salience network and executive control network ([@bib0135]). Hu et al. performed resting state scans in children with acute lymphoblastic leukemia *before* chemotherapy and compared their data to healthy children ([@bib0400]). There were differences in the neural patterns at rest of the default mode network, but no differences in cognitive testing that occurred outside of the scanner. The emergence of differences in neural connectivity prior to treatment may reflect the impact of the disease and treatment progression on the developing brain.

There is a growing body of work that has used cognitive training programs to increase attention, memory, and cognitive flexibility in pediatric cancer survivors. Individuals are often unable to use stimulant medications due to medical contraindication, side effects, or poor response. Thus, either therapist-delivered or computer-delivered cognitive training provides a viable alternative capable of yielding positive results. An extensive review of cognitive training in cancer survivors can be found elsewhere ([@bib0620]). Of note, Kesler et al. tested whether an 8-week cognitive training program would improve cognitive functioning and subsequently change brain activation ([@bib0475]). 17 children and adolescents (ages 7--19 years) with a history of malignancy, radiation, and/or chemotherapy, completed the Wisconsin Sorting Task (testing flexible rule-following behavior) during fMRI before and after cognitive intervention. Post-intervention, participants demonstrated increased activation in the inferior frontal gyrus, medial frontal gyrus and superior frontal gyrus and had higher scores on standard cognitive testing. More recent work by Conklin et al. tested 8- to 16-year-old survivors of acute lymphoblastic leukemia or brain tumors who used a computerized cognitive training program (Cogmed) or were put on a waitlist for 5--9 weeks ([@bib0165]). Children who received the intervention had improvements in working memory and processing speed. They also demonstrated *decreases* in activation during a spatial working memory task in the left lateral PFC and bilateral medial frontal cortex post-treatment. Interestingly, changes in neural activation were not associated with improvements in working memory scores as measured during cognitive testing. The decreased activation, in contrast to what was observed by Kesler et al., was thought to reflect increased neural efficiency, such that survivors who had developed compensatory mechanisms after training had a more efficient and normalized pattern of activation ([@bib0165]). In part, the discrepancies in BOLD activation patterns (increases versus decreases) could be explained by the large age span of participants, as it is these neural circuits that are dynamically changing across childhood into adulthood. While these studies provide insight into the impact of cancer treatment on cognitive function, the age groups are sub-optimally defined. Future work in this area should consider the participant's developmental stage as a moderating variable in order to help clarify discrepancies in findings.

6. Synthesis and next steps {#sec0035}
===========================

A significant challenge with interpretation of the fMRI studies of pediatric cancer survivorship is that data from survivors are often collapsed across children and adolescents. While some studies examined age effects, none of the studies had the statistical power to separate children from adolescents into groups for analyses and/or study different developmental trajectories across age (e.g., continuous age-related increases or decreases in activation, non-linear changes that are adolescent-specific, etc.). Powering studies specifically to examine age in a more fine-grained way often yields critical differences missed by lumping all participants together across developmental stages ([@bib0455]; [@bib0775]; [@bib0855]). Such analyses would be able to disentangle how developmental trajectories may be impacted by cancer onset and treatment, as well as tease apart which findings were a result of normal developmental differences across age groups. Many of the studies assessed whether age at diagnosis and/or years since diagnosis impacted the results, but it was not possible to further separate these findings into child versus adolescent cancer onset.

7. Genetic influences to consider for effects of cancer treatment on the developing brain {#sec0040}
=========================================================================================

Individual differences in genetic makeup have also been examined to understand better why some individuals develop anxiety, PTS, and neurocognitive changes in response to particular life events like cancer, while others do not. While studies between twins and adopted siblings consistently demonstrate a role for genetics in behavior and neuropsychiatric disorders ([@bib0705]), odds ratios for various risk alleles remain low due to contributing influences from many non-genetic factors. The delicate balance between genes and environmental factors (such as early life events or socioeconomic status) may tip differentially from one individual to the next, resulting in varying intermediate biological phenotypes, or endophenotypes ([@bib0335]). In the case of PTS, for example, trauma is necessary but not sufficient for the development of disorder. Some victims may develop subclinical symptomatology or PTSD, whereas others who have experienced a similar trauma might remain resilient ([@bib0565]). Symptom severity for anxiety disorders and PTS also varies greatly between individuals, further suggesting an important role for other contributing factors, including environmental risks and genetic makeup ([@bib0540]). What might be the role of genes in resiliency to the combined physiological and psychological insults associated with child and adolescent cancer? And how might the interplay between these insults, genetics, and the precise neural developmental stage of a patient further complicate who will be most or least susceptible to neurocognitive and emotional impairments? Are individuals with particular genetic polymorphisms prone to being more susceptible or more resilient to the neurocognitive effects of cancer treatment? Understanding how these genetic differences first affect individuals across development -- without factoring cancer into the equation -- will open new windows into the modern era of personalized psychiatric treatment. By exploring how various genetic differences or single nucleotide polymorphisms (SNPs) may alter neural pathways and molecular signaling cascades across development, the fields of cognitive, developmental and molecular neurosciences may collectively offer relevant findings to mental health providers regarding individualized treatment approaches. After first understanding how such genetic differences impact the developing brain in healthy individuals, the field can then explore how these genetic variants might influence outcomes during a pediatric cancer treatment regimen.

When looking at individual susceptibility to neurocognitive impairments associated with cancer regimens, polymorphisms in genes that regulate neural repair and are involved in plasticity and long-term potentiation may be particularly relevant. Genes known to be important for learning and memory formation, such as apoplipoprotein-E-4 (APOE4), brain-derived neurotrophic factor (BDNF), and catechol-O-methyltransferase (COMT) are important to consider. Additionally, individual differences in blood brain barrier (BBB) transporters ([@bib0830]) are likely also critical. While the BBB is capable of providing varying degrees of neuroprotection, treatment-induced changes in neurogenesis at the subcellular level or in resulting neural networks can occur, suggesting the importance of the aforementioned genes, and others, for modifying BBB permeability.

The SNP in the gene BDNF, BDNFVal66Met, is one example, among many, of an interesting candidate to explore for influencing chemotherapeutic impact and secondary effects across development. This SNP in the BDNF gene has been associated with altered susceptibility to a variety of neuropsychiatric disorders including anxiety and depression in adults ([@bib0260]; [@bib0290]; [@bib0340]; [@bib0440]; [@bib0580]; [@bib0800]; [@bib0835]; [@bib0945]) and more recently has been shown to influence PTSD symptoms and cortical thickness in childhood trauma ([@bib0445]). This valine-to-methionine substitution at position 66 of the BDNF prodomain alters normal interactions with the sorting protein, sortilin, resulting in altered trafficking of BDNF into the regulated secretory pathway, which leads to an approximate 30% decrease in activity-dependent release ([@bib0140], [@bib0145]; [@bib0150]; [@bib0240]). This decrease has vast implications, as BDNF is important for the regulation of neuronal development, differentiation, and survival ([@bib0405]), and has a critical role in activity-dependent processes implicated in learning and memory, such as long-term potentiation (LTP) ([@bib0130]; [@bib0505]). In addition to BDNF's early role in assembly of the nervous system, postnatal BDNF levels in the brain remain dynamic, peaking during adolescence, in the rodent ([@bib0470]). How chemotherapeutic agents may alter BDNF expression, trafficking, and signaling during these precise developmental peaks is not currently known.

This BDNF SNP has been genetically knocked into a mouse model, allowing for parallel rodent and human studies. BDNF~Met~ mice recapitulate some of the hallmark phenotypes of human Met allele carriers, including decreased hippocampal volume, as well as impaired hippocampal-dependent contextual fear memory ([@bib0095]; [@bib0145]; [@bib0240]; [@bib0355]; [@bib0890]). Both human Met allele carriers and BDNF^Met/Met^ mice show impairments in extinction of aversive memories compared to non-Met allele carriers ([@bib0845]; [@bib0990]). BDNF expression in the hippocampus is induced during contextual learning ([@bib0350]) and plays a critical role in contextual fear conditioning ([@bib0525]). Deletion of BDNF from the hippocampus leads to impairments in spatial memory and extinction learning in adult rodents ([@bib0370]). BDNF's receptor, TrkB, has also been shown to be essential for hippocampal LTP required for learning ([@bib0570]; [@bib0650]; [@bib0815]). Consistent with the observed behavioral results, mice carrying the Met SNP (BDNF^Met/Met^) exhibit impairments in hippocampal NMDA-receptor dependent LTP ([@bib0610]). Alterations in both Val66Met and TrkB receptor expression have been shown to have developmentally specific effects on learning ([@bib0220]). Recent work has begun to explore the role of activity-dependent regulation of neural development, plasticity, and cancer ([@bib0320]), highlighting the significant interdependence between normal neural signaling and the tumor microenvironment. This work suggests that mechanisms of neural regulation can have a strong impact on tumor growth and has implicated several candidates for this phenomenon, one of which, unsurprisingly, is BDNF ([@bib0320]; [@bib0940]). How the oncological, neurophysiological, and psychological insults of pediatric and adolescent cancer and treatment may impact patients of different genotypes, and across different ages when BDNF levels are peaking developmentally, is of great interest.

Additionally, BDNF and the other aforementioned genes are among a subset of genes postulated to have dual roles in altering BBB integrity during chemotherapy and previously established roles in cognition, learning, and memory ([@bib0830]). It remains unknown how these well-characterized genetic variants -- and many lesser characterized variants -- may change neurocognitive susceptibility to chemotherapeutic treatments and subsequent development of anxiety and PTS, especially across development. Innovative animal models like the ones described above could be leveraged to address these questions.

8. Discussion {#sec0045}
=============

Even when disease remission or cure -- the ultimate goal -- has been achieved in pediatric cancer survivors, effects of the experience may reverberate across many areas of their functioning. Stepping back to consider age at diagnosis, duration and type of treatment, emotional resiliency of the patient, surrounding support networks, socioeconomic status and/or environmental factors, will be critical to inform scientific advances aimed at improving psychosocial treatment approaches and quality of life ([@bib0255]). There are various physiological aspects associated with survivorship, including effects on musculoskeletal and cardiopulmonary systems, alterations in endocrine and reproductive function, as well as risk of secondary disease or relapse ([@bib0615]). But there is also a need to further understand the neurocognitive and psychological effects as they relate to the developing brain. In other words, examining pediatric cancer survivors through a neurodevelopmental lens will offer a perspective that will hopefully clarify secondary challenges associated with survivorship.

Comprehensive reviews of human imaging studies and rodent experiments have established an unambiguous link between cancer treatment early in life and various cognitive alterations in adulthood ([@bib0215]; [@bib0250]; [@bib0545]; [@bib0785]; [@bib0790]), yet the field has not yet teased apart precisely when (infancy, childhood, adolescence, late adolescence) and which treatments (alkylating/DNA-damage agents, antimetabolites, topoisomerase agents, microtubule-destabilizing agents, ionizing radiation, surgery) have specific effects. It is expected, given the dynamic nature of the developing brain, that treatments will result in varying impairments at unique ages. Additional studies that address how the timing of physical and emotional stress due to pediatric cancer influences cognitive control will provide insight into how best to tailor remediation strategies such as cognitive training exercises. Through a combination of parallel rodent experiments and human imaging studies aimed at exploring genetic variants and precise developmental ages, further information can be gained into which treatments might be tailored, and when, to maximize efficacy and minimize unwanted side effects. Given the increasing evidence that cognitive training may be a good candidate for normalizing activity in cognitive control circuitry, it is possible that delivering such training preventively may be particularly efficacious at certain points during development. Further, as peers are particularly motivating for adolescents ([@bib0080]; [@bib0455]; [@bib0850]), work that targets whether adolescent cancer survivors may be more susceptible to both the positive and negative influences of peer feedback will help to further refine our understanding of psychosocial factors that have the potential to impact their outcomes.

Future translational rodent and human studies should use a developmental lens to examine the neural and molecular effects of oncological treatments. This will allow for a fuller understanding of the interaction of the developing brain and cancer treatments on outcomes such as emotional learning, memory, and cognitive control. These findings will provide deeper insight into how best to improve psychological and cognitive outcomes and improve the content of behavioral interventions in pediatric and adolescent cancer survivors. To move the field forward, we should harness what is already known about normative pediatric and adolescent neural circuitry in both mice and humans. By gaining a better understanding of how and when cancer treatments may impact the development of this circuitry, the field can uncover optimal treatments and therapeutic approaches for cancer survivors who may have a somewhat altered neurodevelopmental trajectory. By further exploring individual susceptibilities related to developmental and genetic differences, developmental neuroscientists, psychiatrists, and psychologists may discover new ways to enhance quality of life in pediatric and adolescent survivors.
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